Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
This study is ongoing, but not recruiting participants.
Onyx Therapeutics, Inc.
Information provided by (Responsible Party):
Onyx Pharmaceuticals ( Onyx Therapeutics, Inc. )
First received: August 11, 2011
Last updated: January 31, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||August 2017|
|Estimated Primary Completion Date:||May 2017 (Final data collection date for primary outcome measure)|